ANESTAGEL™

Post-Operative Opioid-Free Pain Management

  • Multi-billion dollar post-operative pain management opportunity
  • Pre-clinical studies complete; FDA pre-IND next
  • Phase I clinical study manufacturing line underway

InSitu Biologics is currently in the investigational pre-clinical stage.
AnestaGel™ is not yet for sale in any geography.

Who We Are

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel™ is expected to be used in post-operative surgical procedures. AnestaGel™ may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernias, and more.
  • AnestaGel™

    • About AnestaGel™

    • 22+ US Patents Issued, with matching OUS positions
    • Hydrogel technology licensed from Cleveland Clinic Foundation
    • Tunable, biocompatible, and pH neutral platform
    • High dose drug-load reservoir capacity with a predictable pharmacological effect
    • Non-opioid pain relief option

    Pre-Clinical Results

    As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment

    300% Longer

    Initial animal study revealed AnestaGel™ lasted up to 300% longer

    8x More Capacity

    AnestaGel™ carried 8 times more payload

    72+ Hours

    AnestaGel™ had full nerve block beyond 72 hours

    See our study at the Journal of Pain Research

    Facebook  |  LinkedIn  |  Twitter  |  Instagram